Qlife collaboration agreement with Hipro biotechnology - potential value of 500 MSEK
Qlife has received many questions related to the potential value of the agreement, and consequently updates as follows:Qlife has on Monday 4[th] of December entered into a final collaboration agreement with Hipro Biotechnology. The parties will from now on work diligently towards achieving market clearance for Egoo Health from the China FDA – expected to take 12-18 months for 3 Egoo tests initially. From the time of market clearance, the value of the collaboration on the Chinese market in the first full year is estimated to be 10-20 percent of Hipro unit sales which currently is approx.